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and a Patient Generated Subjective Global Assessment (PG-SGA)
is used to assess overall nutritional risk. The RD assesses the
macro- and micronutrient adequacy and tolerance of each patient’s
diet. Nutrition standards of care include counseling by the RD on
individual calorie, protein, and vitamin/mineral requirements and
how best to achieve these goals. At our institution three RD’s
provide care in the GVHD clinic. In order to standardize care
across the RD’s and to facilitate communication with the interdis-
ciplinary team, nutrition algorithms were developed. The RD’s
reviewed each of the most common types of GVHD with nutri-
tional implications. They were divided into ﬁve main focuses: 1)
Upper GI (oral/esophageal) GVHD; 2) Lower GI and Liver
GVHD (large volume diarrhea); 3) Anorexia/Failure to Thrive; 4)
Skin GVHD; 5) High Dose Steroid Use. The algorithms are a
series of interventions organized based on such factors as patient’s
ability to eat, adequacy of diet, weight loss, and GI symptoms.
Initial interventions include diet education along with nutritional
and vitamin/mineral supplementation. If these are unsuccessful,
pharmacological interventions and nutrition support via either an
enteral or parenteral route are instituted. Current plans include a
research protocol to evaluate preservation of lean body mass and
improvement in quality of life when nutrition algorithms are fol-
lowed in chronic GVHD patients.
133
A MULTI-INSTITUTIONAL STUDY OF EXTRACORPOREAL PHOTO-
PHORESIS (ECP) WITH UVADEX FOR THE PREVENTION OF ACUTE
GRAFT VS. HOST DISEASE (AGVHD) IN PATIENTS (PTS) UNDERGOING
ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTS
(ALLO-HPCT) WITH MYELOABLATIVE CONDITIONING
Abhyankar, S.1, Bolwell, B.J.2, Shaughnessy, P.J.3, van Besien, K.4,
Ilhan, O.5, Machado, A.6, Dodds, A.7, Grigg, A.8, Prince, H.M.9,
Mistrik, M.10, Gruben, D.11, Thienel, U.11 1. Kansas City Cancer
Center, Kansas City, MO; 2. The Cleveland Clinic Foundation, Cleve-
land, OH; 3. Texas Transplant Institute, San Antonio, TX; 4. Univer-
sity of Chicago, Chicago, IL; 5. Ankara University Medical School,
Ankara, Turkey; 6. Instituto Portugues de Oncologia de Francisco Gentil,
Lisbon, Portugal; 7. St Vincent’s Hospital, Sydney, Australia; 8. Royal
Melbourne Hospital, Melbourne, Australia; 9. Peter MacCallum Cancer
Institute, East, Melbourne, Australia; 10. Klinika Hematologie a Trans-
fuziologie, Bratislavia, Slovakia (Slovak Republic); 11.Clinical Develop-
ment, Therakos, Inc, Exton, PA; 12. The Photopheresis Study Group,.
GvHD remains a major cause of morbidity and mortality after an
allo-HPCT, and ECP has been shown in numerous studies to be
effective in its treatment. ECP has also been used in the prevention
of GvHD in a novel non-myeloablative preparative regimen for
allo-HPCT (Foss, BBMT 9:96, 2003). The incidence of aGvHD
was substantially reduced in this study, possibly due to the effect of
ECP on host dendritic cells, causing alteration in allo-antigen
presentation and reduced donor T-cell activation. We report here
the preliminary results of a multi-institutional phase II study uti-
lizing ECP with Uvadex® in a myeloablative regimen of allo-
HPCT. Treatment with ECP was given on any two days from Day
–10 to –6, followed by cyclophosphamide 60mg/kg for 2 days and
TBI 1200 cGy over three days. Pts. received cyclosporine (CSA)
3-5mg/kg iv from Day –1 (and switched later to PO), to keep levels
between 200-600 ng/ml, and methotrexate 10mg/m2 on Days 1,3,6
and 11 for matched unrelated donors (MUD) and one antigen
mismatched related donors, and 10mg/m2 on Day 1 and 5mg/m2
on Days 3,6 and 11 in matched related donors (MRD), as GvHD
prophylaxis. CSA was continued until Day 100 and then tapered.
Data is available on 34 of 50 enrolled pts. Nineteen pts. are male
and the median age is 37 (range 20 –58). Diagnosis leading to
HPCT includes acute leukemia and myelodysplasia (n  21),
chronic leukemia (n  9), lymphoma (n  3) and other (n  1).
Eighteen pts. received bone marrow (BM) and 16 peripheral blood
(PB) HSCT. Nineteen pts. received matched unrelated or mis-
matched related grafts and 15 matched related. Median time to
engraftment was 20 days for BM and 15 days for PB. ECP was well
tolerated in 33 pts. with one pt. having mild reversible hypoten-
sion. ECP was not discontinued on any pt. At a median follow up
of 85 days (range 5 to 295), acute GvHDGrade II–IV developed in
11 (35.5%) pts. (6 with BM and 5 with PB; 4 with MRD HPCT
and 7 with MUD HPCT). Three pts.died (all MUD HPCT) at a
median of 47 days from HPCT, two from aGvHD (Grades III and
IV), and one from multi-organ failure. 31 pts. are alive while 3 have
relapsed (2 with ALL and 1 NHL). This preliminary analysis
shows that ECP can safely be administered to pts. undergoing
myeloablative allo-HPCT. Further follow up is ongoing to assess
acute and chronic GvHD rates, relapse and transplant related
mortality. Pre and post–ECP lab data on T cell subsets, dendritic
cells and NK cells will also be evaluated.
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Cutaneous, hepatic and gastrointestinal graft-versus-host disease
(GVHD) has been described after both syngeneic and autologous
stem cell transplants. The recent ﬁnding of male DNA in female
donor apheresis products and associations between parous donors
and allogeneic GVHD raise the question of whether persistent
pregnancy-derived fetal microchimerism in donors or recipients
could contribute to the development of sGVHD. Our objective
was to identify the incidence, morbidity, and risk factors for syn-
geneic GVHD (sGVHD) following hematopoietic stem cell trans-
plantation (HSCT) with analysis focused on pregnancy history of
the donor/recipient as potential risk factors. We retrospectively
reviewed the transplant outcomes of 119 adults undergoing syn-
geneic HSCT at our center between 1980 and 2002. We required
diagnostic histological ﬁndings on a biopsy of the skin, intestinal
tract, or liver for the diagnosis of sGVHD. Among 119 syngeneic
transplants, 21 patients had biopsy-proven sGVHD for a preva-
lence of 18%. The median time to developing sGVHDwas 39 days
(range 20-79). In 6 cases, biopsies conﬁrmed multi-organ involve-
ment; sGVHD was the ofﬁcial cause of death in one case. sGVHD
developed in 24% of the women and 13% of the men. A signiﬁ-
cantly higher frequency of sGVHD occurred in the context of a
parous donor (p  0.03, parous donor 11/34, 32%; nulliparous
donor 1/11, 9%; male donor 9/70, 13%) or parous recipient (p 
0.02, parous recipient 11/35, 31%; nulliparous recipient 1/14, 7%;
male recipient 9/70, 13%). Of 26 twin pairs with a parous donor
and parous recipient, 10 (38%) women developed sGVHD versus
no cases in 5 women with a nulliparous donor and recipient (p 
0.10). Other factors signiﬁcantly associated with sGVHD on uni-
variable analysis include older age (p  0.004), Busulfan/Melpha-
lan/Thiotepa conditioning (p  0.002), interleukin-2 therapy (p 
0.017), HLA-A26 type (p  0.02), and more recent transplant year
(p  0.004). In a Cox regression model based on suggestive uni-
variable predictors, only recipient parity and more recent trans-
plant year remained signiﬁcantly associated with sGVHD. The
ﬁnding of recipient parity as a risk factor for sGVHD may support
a role for fetal microchimerism in sGVHD.
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Donor lymphocyte infusion (DLI) is a very efﬁcient therapy for
relapse of chronic myelogenous leukemia in chronic phase (CP-
CML) after allogeneic bone marrow transplantation (BMT). Infu-
sion of allogeneic lymphocytes induces a graft-versus-leukemia
(GVL) effect which produces long term remission in most patients.
However, immunological mechanisms involved in this reaction are
poorly understood. We studied several immunological markers and
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